Biocon Strengthens Control Over Biologics Unit, Issues Shares to Mylan, Other Investors

To settle the acquisition, Biocon issued 17,12,79,553 equity shares on a preferential basis to the allottees. Post-allotment, shareholding stands as: Mylan 6.10%, Serum Institute 3.68%, Tata Capital Growth Fund II 0.41%, and Activ Pine LLP 1.17%, totaling 11.36% for all allottees.

Additionally, Biocon completed the cash acquisition of 7,18,34,691 BBL shares from Mylan for USD 200 million, part of a total approved USD 400 million deal. Following these transactions, Biocon now holds approximately 94% of BBL’s paid-up equity capital on a fully diluted basis.

The Fund Raising Committee meeting authorizing the allotments was held on January 5, 2026, and the company’s total paid-up equity capital increased from INR 6,68,48,18,175 to INR 7,54,12,15,940.

Rajesh U. Shanoy, Company Secretary and Compliance Officer, Biocon Limited, said, “The equity shares allotted shall rank **pari-passu, in all respects, with the existing equity shares of the Company.”